Valproic acid as a therapy for adenomyosis: a comparative case series

Adenomyosis is a difficult disease to manage and currently there is no investigative drug for adenomyosis on the horizon. We have previously reported in a pilot study that valproic acid (VPA) appears to be effective in treating adenomyosis. In this case series, we further evaluated the efficacy of VPA, with or without a progestin-containing intrauterine device, in the treatment of patients with adenomyosis. We recruited 12 patients with confirmed adenomyosis who complained of dysmenorrehea and had enlarged uterus. All patients took VPA for 3 months, then randomly assigned to 2 groups, 1 receiving no further treatment and the other were inserted with a levonorgestrel-releasing intrauterine system (Mirena) and were followed up for an additional 3 months. The primary outcome measures were the severity of dysmenorrhea and uterine size. Both measures were evaluated prior to the drug treatment and 3 and 6 months after the drug treatment, respectively. We found that VPA treatment resulted in complete resolution of dysmenorrhea and an average reduction in uterine size by 26% 6 months after the treatment, regardless of whether Mirena was used or not. Moreover, the amount of menses decreased significantly. Thus, VPA appears to be well tolerated and a promising drug for treating adenomyosis. Similar content being viewed by others

Farquhar C, Brosens I. Medical and surgical management of adenomyosis. Best Pract Res Clin Obstet Gynaecol. 2006;20(4): 603–616. Bergeron C, Amant F, Ferenczy A. Pathology and physiopathology of adenomyosis. Best Pract Res Clin Obstet Gynaecol. 2006;20(4):511–521. Grow DR, Filer RB. Treatment of adenomyosis with long-term GnRH analogues: a case report. Obstet Gynecol. 1991;78(3 pt 2): 538–539. Bragheto AM, Caserta N, Bahamondes L, Petta CA. Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging. Contraception. 2007;76(3): 195–199. Liu X, Guo SW. A pilot study on the off-label use of valproic acid to treat adenomyosis. Fertil Steril. 2008;89(1):246–250. Nie J, Lu Y, Liu XS, Guo SW. Immunoreactivity of progesterone receptor isoform B (PR-B), nuclear factor-kappaB, and IkappaBalpha in adenomyosis. Fertil Steril. 2009;92(3):886–889. Guo SW. Epigenetics of endometriosis. Mol Hum Reprod. 2009;15(10):587–607. Peric H, Fraser IS. The symptomatology of adenomyosis. Best Pract Res Clin Obstet Gynaecol. 2006;20(4):547–555. Gottlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001;20(4):6969–6978. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 2001;276(39):36734–36741. Tunnicliff G. Actions of sodium valproate on the central nervous system. J Physiol Pharmacol. 1999;50(3):347–365. Johannessen CU. Mechanisms of action of valproate: a commentatory. Neurochem Int. 2000;37(2–3):103–110. Critchley HO, Wang H, Jones RL, et al. Morphological and functional features of endometrial decidualization following long-term intrauterine levonorgestrel delivery. Hum Reprod. 1998;13(5):1218–1224. Fong YF, Singh K. Medical treatment of a grossly enlarged adenomyotic uterus with the levonorgestrel-releasing intrauterine system. Contraception. 1999;60(3):173–175. American Academy of Pediatrics Committee on Adolescence; American College of Obstetricians and Gynecologists Committee on Adolescent Health Care, Diaz A, Laufer MR, Breech LL. Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Pediatrics. 2006; 118(5): 2245–2250. Inhaka R, Gentleman RR. R: a language for data analysis and graphics. J Comput Graph Statist. 1996;5(3):1923–1927. Wood C. Adenomyosis: difficult to diagnose, and difficult to treat. Diagn Ther Endosc. 2001;7(2): 89–95. Fedele L, Bianchi S, Frontino G. Hormonal treatments for adenomyosis. Best Pract Res Clin Obstet Gynaecol. 2008;22(2):333–339. Fedele L, Bianchi S, Raffaelli R, Portuese A, Dorta M. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. Fertil Steril. 1997;68(3):426–429. Wentz AC. Chapter 9. Dysmenorrhea, premenstrual syndrome and related discorders. In: HW Jones, Wentz AC, Burnett LS, eds. Novak’s Textbook of Gynecology. 11th ed. New York, NY: Lippincott Williams & Wilkins; 1988:240–262. Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med. 1971;284(15):878–881. Wu Y, Guo SW. Inhibition of proliferation of endometrial stromal cells by trichostatin A, RU486, CDB-2914, N-acetylcysteine, and ICI 182780. Gynecol Obstet Invest. 2006;62(4): 193–205. Nebbioso A, Manzo F, Miceli M, et al. Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. EMBO Rep. 2009; 10(7): 776–782. Wang J, Mahmud SA, Bitterman PB, Huo Y, Slungaard A. Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes. J Biol Chem. 2007;282(39):28408–28418. Dong XF, Song Q, Li LZ, Zhao CL, Wang LQ. Histone deacetylase inhibitor valproic acid inhibits proliferation and induces apoptosis in KM3 cells via downregulating VEGF receptor. Neuro Endocrinol Lett. 2007;28(6):775–780. Lockwood CJ, Krikun G, Hickey M, Huang SJ, Schatz F. Decidualized human endometrial stromal cells mediate hemostasis, angiogenesis, and abnormal uterine bleeding. Reprod Sci. 2009;16(2):162–170. Lindstrom TM, Mohan AR, Johnson MR, Bennett PR. Histone deacetylase inhibitors exert time-dependent effects on nuclear factor-kappaB but consistently suppress the expression of proinflammatory genes in human myometrial cells. Mol Pharmacol. 2008;74(1):109–121. Nie J, Liu XS, Guo SW. Immunoreactivity of oxytocin receptor (OTR) and transient receptor potential vanilloid type 1 (TRPV1) and its correlation with dysmenorrhea in adenomyosis. Am J Obstet Gynecol. 2010;202(4):346.el–8. Mehasseb MK, Bell SC, Pringle JH, Habiba MA. Uterine adenomyosis is associated with ultrastructural features of altered contractility in the inner myometrium. Fertil Steril. 2010;93(7): 2130–2136. Moynihan AT, Hehir MP, Sharkey AM, Robson SC, Europe-Firmer GN, Morrison JJ. Histone deacetylase inhibitors and a functional potent inhibitory effect on human uterine contractility. Am J Obstet Gynecol. 2008;199(2):167.el–7. Bulletti C, DE Ziegler D, Setti PL, Cicinelli E, Polli V, Flamigni C. The patterns of uterine contractility in normal menstruating women: from physiology to pathology. Ann N Y Acad Sci. 2004;1034:64–83. Matalliotakis IM, Kourtis AI, Panidis DK. Adenomyosis. Obstet Gynecol Clin North Am. 2003;30(1):63–82, viii. Flück CE, Yaworsky DC, Miller WL. Effects of anticonvulsants on human p450cl7 (17alpha-hydroxylase/17,20 lyase) and 3beta-hydroxysteroid dehydrogenase type 2. Epilepsia. 2005;46(3):444–448. Stephen LJ, Kwan P, Shapiro D, Dominiczak M, Brodie MJ. Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy. Epilepsia. 2001;42(8): 1002–1006. McIntyre RS, Mancini DA, McCann S, Srinivasan J, Kennedy SH. Valproate, bipolar disorder and polycystic ovarian syndrome. Bipolar Disord. 2003;5(1):28–35. Author information Authors and Affiliations Corresponding author Rights and permissions About this article Cite this article Liu, X., Yuan, L. & Guo, SW. Valproic Acid as a Therapy for Adenomyosis: A Comparative Case Series. Reprod. Sci. 17, 904–912 (2010). https://doi.org/10.1177/1933719110373807 Published: Issue date: DOI: https://doi.org/10.1177/1933719110373807